LDL Cholesterol (Low-Density Lipoprotein Cholesterol)
The LDL Cholesterol test measures the concentration of cholesterol carried within low-density lipoprotein particles in serum, serving as the cornerstone lipid parameter for cardiovascular risk assessment, lipid-lowering therapy initiation, and treatment-to-target monitoring.
1
Biomarkers
Blood (serum)
Sample
1–2 business days
Turnaround
Yes — 9–12 hours preferred when LDL-C is being calculated via the Friedewald equation and for most treatment-decision contexts. Non-fasting collection is acceptable for routine screening per ACC/AHA guidelines when direct LDL measurement is used, but fasting is recommended for triglyceride-sensitive Friedewald calculation and when hypertriglyceridaemia is suspected. # REVIEWER FLAG: Confirm LabCorp's default collection fasting requirement and whether the test code specifies Friedewald calculation or direct LDL-C assay.
Fasting
What is the LDL Cholesterol test?
The LDL Cholesterol test measures the estimated or directly quantified concentration of cholesterol carried within low-density lipoprotein particles in serum. It is the cornerstone lipid parameter in cardiovascular risk assessment, the primary target of lipid-lowering pharmacotherapy, and the most widely used monitoring marker for statin and non-statin therapy efficacy. LDL-C is ordered as part of a standard fasting lipid panel — alongside total cholesterol, HDL cholesterol, and triglycerides — and is used to calculate cardiovascular risk scores, initiate or adjust lipid-lowering therapy, and monitor treatment-to-target in primary and secondary prevention contexts. LDL-C is most commonly reported as a calculated value using the Friedewald equation (Total Cholesterol − HDL − [Triglycerides ÷ 5]) rather than a directly measured concentration, though LabCorp offers direct LDL-C measurement that remains clinically valid when triglycerides are markedly elevated — a scenario where the Friedewald calculation becomes unreliable. In routine practice, the Friedewald calculation is adequate when triglycerides are below 400 mg/dL. Beyond LDL-C, practitioners evaluating residual cardiovascular risk — particularly in patients with insulin resistance, metabolic syndrome, or discordance between LDL-C and non-HDL cholesterol — should consider ApoB and LDL particle number (NMR lipoprofile) as complementary markers that capture the atherogenic burden of small dense LDL particles not fully represented by standard LDL-C. # REVIEWER FLAG: Confirm whether LabCorp reports LDL-C via Friedewald calculation or direct assay by default for this test code, and whether the ordering practitioner can specify direct LDL measurement.
What does the LDL Cholesterol test measure?
Low-density lipoprotein particles are the primary carriers of cholesterol in the systemic circulation, transporting esterified and unesterified cholesterol from the liver to peripheral tissues. LDL particles are generated from very-low-density lipoprotein (VLDL) through sequential lipolysis by lipoprotein lipase and hepatic lipase, with intermediate-density lipoprotein (IDL) as the transitional form. Each LDL particle contains a single molecule of apolipoprotein B-100 (ApoB-100), which mediates hepatic and peripheral LDL receptor binding and cellular cholesterol uptake via clathrin-mediated endocytosis. LDL particle size is heterogeneous — small, dense LDL particles are more atherogenic per unit of cholesterol mass than large buoyant particles, a distinction not captured by standard LDL-C measurement. Circulating LDL half-life is approximately 2–3 days.
LDL cholesterol is the primary lipid target in cardiovascular risk assessment and management and is the most extensively validated modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Elevated LDL-C drives endothelial dysfunction, subendothelial lipoprotein deposition, macrophage foam cell formation, and atherosclerotic plaque development through both direct and oxidative mechanisms. A causal relationship between LDL-C and ASCVD is established through Mendelian randomisation studies, statin trials, and familial hypercholesterolaemia cohort data. LDL-C is used to stratify cardiovascular risk, guide lipid-lowering therapy initiation and titration, and monitor treatment response — with lower achieved LDL-C consistently associated with greater reduction in major adverse cardiovascular events across the evidence base.
Why is the LDL Cholesterol test ordered?
- Routine cardiovascular risk assessment — baseline lipid panel in adults aged 20 and over as part of primary prevention cardiovascular health screening, per ACC/AHA and USPSTF recommendations
- Initiation of lipid-lowering therapy — establishing pre-treatment LDL-C to guide statin intensity selection and document baseline before pharmacotherapy, per ACC/AHA 2018 cholesterol guidelines risk-stratified treatment framework
- Monitoring lipid-lowering therapy response — serial LDL-C assessment 4–12 weeks after initiating or adjusting statin, ezetimibe, PCSK9 inhibitor, or other lipid-lowering agent to confirm treatment-to-target achievement
- Secondary cardiovascular prevention — established ASCVD (prior MI, stroke, TIA, peripheral arterial disease, coronary revascularisation) where LDL-C target is <70 mg/dL (ACC/AHA) or <55 mg/dL (ESC/EAS) and monitoring is ongoing
- Familial hypercholesterolaemia evaluation — markedly elevated LDL-C (≥190 mg/dL) without secondary cause, particularly with positive family history of premature cardiovascular disease or tendon xanthomata, where genetic cause requires clinical characterisation
- Metabolic syndrome and insulin resistance workup — LDL-C alongside triglycerides, HDL-C, fasting glucose, and non-HDL-C to characterise the atherogenic dyslipidaemia pattern common in this population
- Thyroid, renal, or hepatic disease evaluation — secondary hypercholesterolaemia from hypothyroidism, nephrotic syndrome, or cholestatic liver disease where elevated LDL-C requires causal workup before lipid-lowering therapy is initiated
- Integrative and functional medicine cardiovascular assessment — LDL-C as part of an expanded lipid panel including ApoB, Lp(a), LDL particle number, and inflammatory markers (hs-CRP) for comprehensive atherogenic risk characterisation
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
Yes — 9–12 hours preferred when LDL-C is being calculated via the Friedewald equation and for most treatment-decision contexts. Non-fasting collection is acceptable for routine screening per ACC/AHA guidelines when direct LDL measurement is used, but fasting is recommended for triglyceride-sensitive Friedewald calculation and when hypertriglyceridaemia is suspected. # REVIEWER FLAG: Confirm LabCorp's default collection fasting requirement and whether the test code specifies Friedewald calculation or direct LDL-C assay.
Collection method
Venipuncture at patient service centre
Turnaround
1–2 business days
Collection notes
Standard venipuncture into a serum separator tube (SST / gold top). If fasting specimen, confirm the patient has fasted for 9–12 hours prior to collection — water is permitted. Document current lipid-lowering medications (statin, ezetimibe, PCSK9 inhibitor, fibrate, niacin), dose, and duration on the requisition form. Document any recent acute illness, hospitalisation, or surgery in the preceding 6–8 weeks, as these significantly affect LDL-C and invalidate the result as a habitual baseline. # REVIEWER FLAG: Confirm LabCorp tube type, minimum volume, and any special handling requirements for this test code.
Specimen requirements
Minimum 0.5 mL serum. Centrifuge and separate serum from cells within 2 hours of collection. Stable at 2–8°C for up to 5 days; stable frozen at −20°C for extended storage.
What can affect LDL Cholesterol results?
When LDL-C is calculated via the Friedewald equation, postprandial triglyceride elevation reduces the calculated LDL-C (since triglycerides ÷ 5 is subtracted), potentially underestimating true LDL-C. For direct LDL-C measurement, fasting status has minimal effect. ACC/AHA guidelines now permit non-fasting lipid panels for routine risk assessment, but fasting specimens remain preferable when triglyceride levels are expected to be elevated or when the Friedewald calculation is being used for treatment decisions.
The Friedewald equation becomes unreliable when triglycerides exceed 400 mg/dL, systematically underestimating LDL-C. Direct LDL-C measurement or the Martin-Hopkins equation — validated for accuracy across a wider triglyceride range — should be requested in patients with hypertriglyceridaemia. Practitioners should flag this limitation when interpreting Friedewald-calculated LDL-C in patients with known triglyceride elevation.
Statins inhibit HMG-CoA reductase, reducing hepatic cholesterol synthesis and upregulating LDL receptor expression, producing a 30–55% LDL-C reduction depending on statin intensity. PCSK9 inhibitors produce additional 50–60% LDL-C reduction by preventing LDL receptor degradation. Ezetimibe reduces LDL-C by approximately 15–20% through inhibition of intestinal cholesterol absorption via NPC1L1. Medication and dose must be documented when interpreting LDL-C to assess on-treatment performance against target.
Thyroid hormone regulates LDL receptor expression and hepatic cholesterol metabolism. Hypothyroidism reduces LDL receptor activity and decreases cholesterol catabolism, raising LDL-C — sometimes substantially. Secondary hypercholesterolaemia from hypothyroidism should be excluded with TSH measurement before initiating lipid-lowering pharmacotherapy, as LDL-C typically normalises with thyroid hormone replacement.
Urinary protein loss in nephrotic syndrome stimulates compensatory hepatic lipoprotein synthesis, including increased VLDL and LDL production, producing a secondary hyperlipidaemia. LDL-C elevation in the context of significant proteinuria should prompt urinalysis and renal function assessment to identify the underlying cause before lipid-lowering therapy is attributed solely to primary hypercholesterolaemia.
Acute phase response and systemic inflammation acutely reduce LDL-C by up to 30–40% through cytokine-mediated changes in lipoprotein metabolism. LDL-C measured during hospitalisation, acute infection, myocardial infarction, or major surgery will underestimate the patient's habitual LDL-C. Fasting LDL-C measured at least 6–8 weeks after resolution of the acute illness provides a reliable baseline.
What do LDL Cholesterol results mean?
Elevated
LDL-C above 130 mg/dL in a patient with cardiovascular risk factors, or above 100 mg/dL in a patient with established ASCVD or diabetes, warrants clinical attention and treatment consideration. LDL-C ≥190 mg/dL in a young adult without secondary cause should prompt evaluation for familial hypercholesterolaemia using the Dutch Lipid Clinic Network or Simon Broome criteria. Elevated LDL-C should always be interpreted in the context of the full lipid panel, global ASCVD risk score (PCE, SCORE2, or equivalent), and secondary causes (hypothyroidism, nephrotic syndrome, cholestatic liver disease, medications including thiazides, corticosteroids, and retinoids) before treatment decisions are made.
Normal
LDL-C within the optimal range (<100 mg/dL) in a low-risk patient on no lipid-lowering therapy is reassuring for standard cardiovascular risk assessment purposes. In functional and preventive medicine contexts, practitioners should also assess non-HDL cholesterol, ApoB, and Lp(a) before concluding that cardiovascular lipid risk is fully characterised — particularly in patients with insulin resistance or a strong family history of premature ASCVD, where discordance between LDL-C and LDL particle number is common.
Reduced
LDL-C below 70 mg/dL is the treatment target for high-risk and very-high-risk patients on lipid-lowering therapy and represents successful therapeutic lowering rather than a pathological finding in this context. Unexpectedly low LDL-C in an untreated patient — particularly below 40 mg/dL — warrants consideration of secondary causes including hyperthyroidism, chronic liver disease with impaired lipoprotein synthesis, malabsorption syndromes, or malignancy. Very low LDL-C in the context of markedly elevated triglycerides may also indicate the Friedewald calculation is producing an artefactually low result.
Note: The most clinically important caveat is that LDL-C is a concentration measure of cholesterol mass and does not capture LDL particle number or size — two determinants of atherogenic risk that are particularly discordant in patients with insulin resistance, metabolic syndrome, and hypertriglyceridaemia. A patient with low LDL-C but high triglycerides and low HDL-C may harbour a large number of small, dense, highly atherogenic LDL particles despite an apparently reassuring LDL-C value. ApoB (one molecule per LDL, IDL, and VLDL particle) or direct LDL particle number measurement is required to identify this discordant pattern. Additionally, Friedewald-calculated LDL-C is inaccurate above 400 mg/dL triglycerides, and all LDL-C measurements are unreliable within 6–8 weeks of acute illness or major surgery.
Frequently asked questions
LDL cholesterol measures the concentration of cholesterol carried within low-density lipoprotein particles — the primary cholesterol-carrying particles in the circulation responsible for delivering cholesterol to peripheral tissues. Elevated LDL-C is causally established as a driver of atherosclerotic plaque formation and cardiovascular disease, and is the primary target of lipid-lowering therapy. The causal relationship is supported by Mendelian randomisation studies, familial hypercholesterolaemia cohort data, and decades of statin trial evidence.
How to access the LDL Cholesterol test
The LDL Cholesterol reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: May 23, 2026
Last reviewed: May 23, 2026
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. (2019)
- Mach F, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. (2020)
- Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. Eur Heart J. (2017)
- Martin SS, et al. Comparison of a Novel Method vs the Friedewald Equation for Estimating Low-Density Lipoprotein Cholesterol Levels From the Standard Lipid Panel. JAMA. (2013)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…
cardiovascular
Apo-B
The Apolipoprotein B (Apo-B) test counts the total number of atherogenic lipoprotein particles, since each LDL, VLDL, IDL, and lipoprotein(a) particle carries one apolipoprotein B. It is a strong cardiovascular risk marker, in many analyses superior to LDL cholesterol because it captures particle number rather than cholesterol content, and is especially informative where LDL cholesterol…
cardiovascular
Lp(a)
The lipoprotein(a) [Lp(a)] test measures a genetically determined, LDL-like particle that is an independent risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis. Because its level is largely inherited and stable through life, a single measurement usually suffices to establish lifelong risk.